New insider activity at Danaher ( (DHR) ) has taken place on February 11, 2025.
Director Alan Spoon recently sold 550 shares of Danaher stock, amounting to a transaction value of $113,553.
Recent Updates on DHR stock
Danaher has experienced significant developments in the past 24 hours, with a notable price target adjustment due to its recent earnings report. Argus lowered Danaher’s price target following a Q4 earnings miss, citing near-term headwinds such as market weakness in China and a mild winter flu season. These factors, along with interest rate volatility affecting equity valuations, contributed to the revised outlook. Despite this, Danaher’s management remains optimistic about long-term prospects in supporting biologic therapeutics development. Additionally, Raymond James downgraded Danaher to Market Perform from Outperform, expressing concerns about the company’s outlook and growth potential compared to its peers, leading to a murkier outlook post-Q4 report.
More about Danaher
YTD Price Performance: -10.03%
Average Trading Volume: 3,557,785
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $149.3B